Analysis of the inflammatory network in benign prostate hyperplasia and prostate cancer

被引:129
|
作者
König, JE
Senge, T
Allhoff, EP
König, W
机构
[1] Ruhr Univ Bochum, Marienhosp Herne, Dept Urol, D-44627 Herne, Germany
[2] Univ Magdeburg, Dept Urol, D-39106 Magdeburg, Germany
[3] Univ Magdeburg, Dept Med Microbiol, D-39106 Magdeburg, Germany
来源
PROSTATE | 2004年 / 58卷 / 02期
关键词
prostate tissue; benign hyperplasia; prostate carcinoma cell lines; inflammatory mediators; chemotaxins; chemotaxin receptors;
D O I
10.1002/pros.10317
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
INTRODUCTION. The complexity of acute and chronic inflammatory processes may either lead to benign prostate hyperplasia (BPH) and/or prostate cancer. Obviously, various tissue cells are activated by chemokines via different chemotaxin receptors which then trigger subsequent processes in angiogenesis, cellular growth, and extravasation as well as neoplasia. METHODS. Using the surgically obtained tissue of patients (n = 36) with BPH or prostate carcinoma (PCA), we studied among others the expression of chemokines (Rantes, IL-8), chemotaxin receptors (CXCR-3 and -4, CCR-3, CCR-5), of matrixmetalloproteinases (MMP-2 and 9), of Toll-like (TL) receptors 1, 2,3,4,5,7, and 9 and of the inducible cyclooxygenase-2 (cox-2) by RT-PCR. Further support for the different properties of tissue from PCA was obtained using two different PCA cell lines (PC3 = androgen resistant cell) or LNCAP cells (androgen sensitive) with emphasis on IL-8,11-6, and PGE(2) release. Cell lines were stimulated with either the tumor necrosis factor-alpha (TNF-alpha) and lipopolysacharide (LPS) over time. In addition to cytokine release, the quantification of mRNA by lightcycler for cox-2, IL-6, and IL-8 was performed on these cell lines. RESULTS. Remarkable differences in expression were obtained by RT-PCR when BPH tissue versus PCA was analyzed. Expression of CXCR-1 after incubation with LPS and TNF-a showed time-dependent differences for androgen-sensitive LNCAP as compared to androgen-resistant PC-3 cells. TNF-alpha incubation leads to a time-dependent induction of cox-2 expression unlike to activation with LPS. Differences with regard to cox-2, IL-6, and IL-8 expression were seen by quantitative lightcycler analysis. Significant differences were also observed when TL receptors 4, 5, 7, and 9 were analyzed which were significantly expressed in BPH- as compared to PCA-tissue. CONCLUSIONS. Our data clearly demonstrate that various inflammatory and cell biological cascades are involved which either lead to BPH or can be linked to the development of PCA. The exact cell biological mechanisms may provide novel therapeutic options in the treatment of both diseases.
引用
收藏
页码:121 / 129
页数:9
相关论文
共 50 条
  • [1] Cell biological and immunological mechanisms in benign prostate hyperplasia and prostate cancer - Role of the inflammatory network
    Koenig, J
    Senge, T
    Pannek, J
    Boernig, H
    Koenig, W
    Allhoff, EP
    Koenig, B
    [J]. JOURNAL OF UROLOGY, 2002, 167 (04): : 219 - 220
  • [2] BENIGN HYPERPLASIA AND CANCER OF PROSTATE
    不详
    [J]. BRITISH MEDICAL JOURNAL, 1975, 1 (5948): : 2 - 3
  • [3] BIOCHEMICAL MARKERS IN PATIENTS WITH PROSTATE CANCER AND BENIGN PROSTATE HYPERPLASIA - A MULTIVARIATE ANALYSIS
    Strittmatter, F.
    Stieber, P.
    Nagel, D.
    Hofmann, K.
    Stief, C. G.
    Waidelich, R.
    [J]. ANTICANCER RESEARCH, 2008, 28 (6B) : 4058 - 4058
  • [4] Benign prostatic Hyperplasia, prostate cancer
    Mathieu, R.
    [J]. PROGRES EN UROLOGIE, 2016, 26 (03): : F65 - F66
  • [5] BENIGN PROSTATIC HYPERPLASIA AND CANCER OF PROSTATE
    WILLIAMS, RD
    BLACKARD, CE
    [J]. LANCET, 1974, 2 (7891): : 1265 - 1265
  • [6] Benign prostatic hyperplasia, prostate cancer
    Lebdai, S.
    [J]. PROGRES EN UROLOGIE, 2017, 27 (01): : F18 - F20
  • [7] Benign prostatic hyperplasia, prostate cancer
    Mathieu, R.
    [J]. PROGRES EN UROLOGIE, 2016, 26 (01): : F20 - F22
  • [8] Benign prostatic hyperplasia, prostate cancer
    Mathieu, R.
    [J]. PROGRES EN UROLOGIE, 2015, 25 : F82 - F84
  • [9] Benign prostatic hyperplasia and prostate cancer
    Guess, HA
    [J]. EPIDEMIOLOGIC REVIEWS, 2001, 23 (01) : 152 - 158
  • [10] Benign prostatic hyperplasia, cancer of the prostate
    Lebdai, S.
    [J]. PROGRES EN UROLOGIE, 2017, 27 (02): : F40 - F42